What Zimmer Biomet's latest 10-Q says: 11 signals
Zimmer Biomet filed its latest 10-Q with the SEC on Aug 5, 2026. It discusses acquisition announced, capex increase and cost reduction.
Public (ZBH)Medical Equipment Manufacturing10,000+ employeeszimmerbiomet.comLinkedIn
- Filed
- Aug 5, 2026
- Filings
- 2
- Signals
- 23
10-Q · latest 10
What Zimmer Biomet's 10-Q filings say
- SEC EDGAR
10-Q
Filed · 11 signals
Spending $245M+ on two recent acquisitions, creating urgent system integration needs.
The company spent ~$245M in cash on two acquisitions after Q2 2026, with up to $210M more in contingent payments.
$245M
Initial cash consideration for two acquisitions subsequent to Q2 2026
ERP
Zimmer Biomet announces two new acquisitions totaling up to $455M
The company is actively acquiring, with one deal closed and another pending regulatory approval for a combined total of up to $455M.
$455M
Total potential consideration for two acquisitions ($245M initial cash + $210M contingent)
ZBH targets $175M in annual cost savings by 2027 via its 2025 Restructuring Plan.
The company is executing a restructuring plan to reduce gross annual pre-tax operating expenses by $175 million by the end of 2027, creating significant pressure for operational efficiency and cost-saving technology adoption across the organization.
$175M
Targeted gross annual pre-tax operating expense reduction by end of 2027
enterprise resource planning
Executing major restructuring plan to cut $175M in annual operating expenses by 2027
This major cost-cutting initiative creates intense pressure to find efficiencies across the organization.
$175M
Targeted gross annual pre-tax operating expense reduction by end of 2027
ZBH spends $245M+ on two new acquisitions, creating immediate integration challenges.
The company recently spent ~$245 million on two acquisitions, with up to $210 million in additional contingent consideration.
$245M
Initial cash consideration for two recent acquisitions
enterprise resource planning
ZBH commits up to $300M to an investment fund for healthcare innovation.
$300M
Capital commitment to an investment fund over a four-year period
ZBH in multi-year dispute with IRS, facing potentially significant payments.
The company is defending against IRS proposed adjustments for multiple audit periods (2013-2019), which could result in significant future cash payments, creating pressure on the finance and tax departments to manage risk and reporting.
Acknowledges risk of disruptions and unplanned expenses from ERP system updates.
The company flags its enterprise resource planning (ERP) and other system updates as a significant operational risk, suggesting potential struggles with a current or planned implementation.
ERP
ZBH discloses $137.9 million in estimated liabilities for ongoing litigation.
The company has accrued a significant $137.9 million liability for various litigation matters, creating pressure on legal and finance teams to manage costs, risk, and compliance, which can trigger reviews of legal tech and risk management solutions.
$137.9M
Estimated total liabilities for all litigation matters
- SEC EDGAR
10-Q
Filed · 12 signals
Paul Stellato is serving as Interim Chief Financial Officer as of May 2026
The presence of an Interim CFO, Paul Stellato, signals a period of transition in financial leadership.
Showing 10 of 23 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Zimmer Biomet earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Making leadership and governance changes in US and international businessesThe company is actively changing leadership and reporting lines in international markets, US sales (ASC, S.E.T., key accounts), and its restorative therapies unit to address performance issues. These changes often trigger reviews of existing processes and vendor relationships. | |
| Making meaningful commercial investments and leadership changes to drive growth.The company is overhauling its commercial organization by installing new leadership for ASCs, S.E.T., and key accounts, and specializing its sales force for robotics. This signals budget allocation for talent and restructuring to fix execution issues and accelerate growth. | |
| Focused on integrating two significant M&A deals: Paragon 28 and MonogramZBH is actively integrating two major acquisitions, which involves combining commercial operations, product lines, and back-office systems. This period of integration creates opportunities for consulting services and technology vendors specializing in M&A integration, system consolidation, and change management. | |
| Overhauling sales incentive plans to drive growth and marginThe company is implementing a new, disciplined sales incentive plan at all levels, from senior management to sales reps, tying compensation directly to revenue growth and margin. This signals a major focus on sales performance management and tools that can track and optimize these new KPIs. | |
| Absorbing a significant $40M tariff headwind in 2025The company is managing a $40 million financial impact from tariffs, which pressures margins and increases the focus on cost control and operational efficiency. This creates an opening for solutions that can reduce manufacturing costs, optimize the supply chain, or improve overall financial discipline. | |
| CMFT business grew over 20%, remains a key investment area.The craniomaxillofacial thoracic (CMFT) business is a high-growth engine, expanding over 20% due to new product introductions. The CEO identified it as a continued recipient of investment, signaling a focus on diversifying into high-performing medical device segments. |
Signal API · MCP
Track Zimmer Biomet with the Signal API
One POST /v1/companies/enrich call with zimmerbiomet.com returns Zimmer Biomet 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"zimmerbiomet.com","signal_types":["sec-10q"],"limit":20}'Same industry
10-Q at related companies
Questions about Zimmer Biomet 10-Q
When did Zimmer Biomet file its latest 10-Q?
What did Zimmer Biomet disclose in its latest 10-Q?
What did Zimmer Biomet say on its recent earnings calls?
Where can I read Zimmer Biomet's 10-Q filing?
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .